GlassScriptPhysician profile
Mark H Fletcher
NPI 1225021371
$40,677.46
in general payments reported to CMS, 2019-2025
56 companies · $3,245 in 2025
The $3,245 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $5,441 · 2021: $2,242 · 2022: $3,062 · 2023: $3,112 · 2024: $3,196 · 2025: $3,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,553.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20,568.72 | 2019-2024 | |
| Abbvie INC. | $3,309.95 | 2019-2025 | |
| Allergan, INC. | $1,974.04 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,261.26 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $878.65 | 2019-2025 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $859.35 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sk Life Science, INC. | $790.24 | 2020-2025 | Xcopri |
| Livanova USA, INC. | $783.78 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Pfizer INC. | $640.61 | 2019-2025 | |
| Amgen INC. | $555.31 | 2019-2025 | Uplizna, Aimovig |
| Acadia Pharmaceuticals INC | $554.63 | 2019-2025 | Nuplazid |
| Jazz Pharmaceuticals INC. | $535.42 | 2019-2023 | |
| Ucb, INC. | $531.48 | 2019-2025 | Rystiggo, Nayzilam, Zilbrysq |
| Acorda Therapeutics, INC | $511.98 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $500.61 | 2022 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $496.42 | 2019-2025 | Vumerity, Skyclarys, Tysabri |
| Harmony Biosciences LLC | $423.29 | 2022-2025 | Wakix |
| Genentech USA, INC. | $387.65 | 2019-2024 | Ocrevus, Ocrevus Zunovo |
| Lilly USA, LLC | $381.70 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Biohaven Pharmaceuticals, INC. | $377.36 | 2021 | |
| Lundbeck LLC | $329.58 | 2019-2025 | Vyepti, Rexulti |
| Emd Serono, INC. | $325.65 | 2020-2025 | Mavenclad, Mavenclad |
| Tanabe Pharma America, INC. | $317.44 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $313.29 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $303.70 | 2021-2025 | Rytary, Crexont, Ongentys |
| Neurocrine Biosciences, INC. | $300.09 | 2021-2025 | Ingrezza, Ongentys |
| Piramal Critical Care | $288.55 | 2019-2025 | |
| Argenx US, INC. | $285.92 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Supernus Pharmaceuticals, INC. | $247.16 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $229.28 | 2021-2025 | Xeomin, Inbrija |
| Astrazeneca Pharmaceuticals LP | $110.25 | 2022-2025 | Wainua |
| Neurelis, INC. | $107.12 | 2025 | Valtoco |
| Medtronic USA, INC. | $102.37 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $97.05 | 2020-2024 | |
| Celgene Corporation | $92.19 | 2021-2024 | Zeposia |
| Medtronic, INC. | $87.12 | 2021-2025 | Synchromedii |
| Otsuka America Pharmaceutical, INC. | $83.04 | 2023-2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $76.84 | 2022-2023 | Onpattro |
| Greenwich Biosciences, INC. | $73.79 | 2019 | |
| Csl Behring | $68.42 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $64.52 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $54.66 | 2022-2023 | Trudhesa |
| Springworks Therapeutics, INC. | $50.48 | 2025 | Gomekli |
| Merz North America, INC. | $46.92 | 2020 | |
| Ani Pharmaceuticals, INC. | $41.73 | 2025 | Purified Cortrophin Gel |
| Tg Therapeutics, INC. | $39.79 | 2023 | |
| Eisai INC. | $37.41 | 2024-2025 | |
| Corium, LLC | $33.01 | 2022-2023 | Adlarity |
| Takeda Pharmaceuticals U.S.A., INC. | $31.27 | 2020-2025 | Hyqvia |
| Amylyx Pharmaceuticals, INC. | $21.34 | 2023 | Relyvrio |
| Avion Pharmaceuticals | $18.50 | 2022 | |
| Boston Scientific Corporation | $17.25 | 2023 | Wavewriter Alpha Prime 16 |
| Sumitomo Pharma America, INC. | $16.53 | 2023 | Aptiom |
| Averitas Pharma INC. | $15.89 | 2023 | Qutenza |
| Resmed Corp | $15.46 | 2025 | |
| Sanofi-Aventis U.S. LLC | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fletcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.